Health Research Authority (HRA) What do you need to know?

Similar documents
UK COMPATIBILITY HEALTH RESEARCH AUTHORITY APPROVAL WHAT IS HEALTH RESEARCH AUTHORITY APPROVAL?

Setting up new studies where NBT are sponsor

Research Study Amendments

Sally Burtles, Director of Research Services & Business Development

MHRA regulatory centre and Research Ethics Service (RES) combined ways of working pilot Instructions to sponsors (version 2.1)

LCRN Guidance Suite. V1.0 March Document Ref No: D05. Version 1.0 March 2016 Page 1 of 8

STANDARD OPERATING PROCEDURE

HRA Approval performance to September 2018

UK wide consistency and IRAS developments

PERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES

A step by step guide to using IRAS to apply to conduct research in or through the NHS/HSC.

End of Study Notification, Close-Out and Reporting Sponsored Research. Noclor/Spon/S11/01. SOP Reference ID:

PERFORMANCE IN INITIATING CLINICAL RESEARCH (PI) CLINICAL TRIAL FEEDBACK PROCESS HRA APPROVED TRIALS

Confirming Research Study Capacity and Capability

STP Project Ethical Approval Process

The Pathway of Project Approvals. Charlotte Davies- Research and Development Operations Manager

NHS REC Booking & Submission Changes Spring 2014

EDGE. Frequently Asked Questions. Clinical Research Network North Thames. August 2016/ Ziya Adnan, Business Intelligence Manager

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products

Writing a Protocol for CTIMPs

STANDARD OPERATING PROCEDURE FOR RESEARCH. 14. Amendments to Research Studies

Joint Research Office

Research Governance Policy and Procedure

STUDY CLOSURE AND ARCHIVING

NHS R&D Forum Response CRN Study Support Service Effective Study Start-Up SOP. Version Consultation Draft, 15 JUNE 2015

Collaborative working between sponsors and NHS organisations in England for HRA Approval studies, where no formal

Short Introduction. Main Introduction. The Basics

Sponsorship of Clinical Research Studies

STUDY DOCUMENTS. DOCUMENT NO.: CR007 v4.0. Marise Buçukoğlu ISSUE DATE: 07 MAR 2017 EFFECTIVE DATE: 21 MAR INTRODUCTION

Contents 1. OVERVIEW APPLICABILITY TRIAL INFORMATION PHARMACY REGISTRATION & SET-UP PHARMACY ACTIVATION PATI

NUH PHARMACY CLINICAL TRIALS. Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014

Investigator Site File Index (CTIMP)

RESEARCH AUDIT Standard Operating Procedure

Industry pack Guidance for the set-up of hosted clinical trials

Louise Brook Clinical Trials Quality Monitor. Date

Code break is also known as breaking the blind and involves un-blinding a participant so that the treatment allocation is made known.

Business Planning for 2014/15

How to Apply for Ethics (Non-CTIMPs) including Sponsorship

Index of Standard Operating Procedures for all research Sponsored by the UHL

HRA Statement of Activities

Trust Board Meeting: Wednesday 8 July 2015 TB

HRA Approval in Primary Care Settings Principles of Study Set-Up

RESEARCH SUPPORT SERVICES FRAMEWORK. Streamlining the management and governance of R&D studies in the NHS

RESEARCH IN HUMAN SUBJECTS OTHER THAN CLINICAL TRIALS OF INVESTIGATIONAL MEDICINAL PRODUCTS

STANDARD OPERATING PROCEDURE

Research & Development. J Illingworth and S Moffat. Research, pharmacy and R&D staff

RESEARCH AND INNOVATION (R&I) Research Capacity and Capability Assessment Guidance

Once notified of the end of trial, a Research Manager, on behalf of the Sponsor, will contact the CI to arrange a close down monitoring visit.

PREPARING TO RUN A TRIAL

RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down

Standard Operating Procedure

2015 SAP Quality Awards Questions in Online Application

Standard Operating Procedure (SOP) for the Development, Management & Control of Research-Related SOPs

Research Study Close-down and Archiving Procedures

NIHR CRN Quarterly Performance Report Quarter /18

Index of Standard Operating Procedures for all research Sponsored by the UHL

Appendix: 4.3b APPENDIX D TO THE SERVICE LEVEL AGREEMENT BETWEEN NEL CSU AND ISLINGTON CCG. SLA Performance Measures. Core Services. March 2013 (v5.

STANDARD OPERATING PROCEDURE SOP 310

Inspections: an academic perspective

Guidance on conducting consultations in the HRA Internal HRA guidance only

The role of the Clinical Trials Unit Emma Hall PhD CStat Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU)

Comparison of admission rates to neonatal units between PO screening and non-po screening Units

Module Samples. AQP Modules. ContractsAdvance

Phase 1 studies and The Over- Volunteering Prevention System (TOPS)

Supply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017

HRA/Ethics Approval for Health-Related Research

HEALTH RESEARCH AUTHORITY BOARD MEETING

NIHR Local Clinical Research Networks

ETZ Timesheet Manager Contractor User Guide

Central Portfolio Management System

NRES Committee East of England - Cambridge Central Royal Standard Place Nottingham NG1 6FS

COMBINED RISK ASSESSMENT

RDSOP28 Randomisation and Unblinding in Clinical Trials of an Investigational Medicinal Product (CTIMPs)

Date: 23 rd December 2014 Version 5 Page 1 of 8 STANDARD OPERATING PROCEDURE FOR TRIAL INITIATION AND SITE SET UP (NWORTH 3.03)

Investigator Site File Index (Medical Devices)

STANDARD OPERATING PROCEDURE

ETZ Timesheet Manager Contractor User Guide

Integrated Research Application System (IRAS)

Public Consultation Paper: Assessment of the Functioning of the Clinical Trials Directive 2001/20/EC

SOP14a: Standard Operating Procedure Applying for Ethical Approval

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria

Supporting and applying research in the NHS. 1. Overview

Primary Care mcta 2013: Guidance for use

Conducting Clinical Trials of Investigational Medicinal Products

RD SOP32 Gaining MHRA Approval

Document Title: Handling of drug alerts and recalls of IMPs

NIHR CRN High Level Objectives Quarterly Performance Report. Quarter /16

STANDARD OPERATING PROCEDURE

STANDARD OPERATING PROCEDURE SOP 410. Set up and Initiation of an Investigator Site

Site Initiation and Activation

Development Safety Update Report Guidance

Essential Healthcare Research Governance Processes. Cindy Cooper, Lindsay Unwin and Judith Cohen, UoS

NIHR CRN High Level Objectives Year End Performance Report /18

Computer System Validation & Backup

Scotland A REC 2 nd Floor Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG

IMP Management and Accountability

QUEEN S UNIVERSITY BELFAST. Regulations for Research Involving Human Participants

House of Commons Science and Technology Committee: Inquiry on clinical trials and disclosure of data

CADTH COMMON DRUG REVIEW. Procedure for the CADTH Common Drug Review

Transcription:

Health Research Authority (HRA) What do you need to know?

Background why another change?

Cohorts Cohort Type of Study Live date 1 Health services research not requiring REC review 11 th May 2015 2 Studies in primary care only 10 th August 2015 3 Studies which are not clinical trials or clinical investigations 4 Clinical trials and clinical investigations in secondary care 30 November 2015 March 2016 5 Single site, site sponsored studies March 2016 6 Studies solely for educational purposes March 2016 Fully implemented from 31 st March 2016

The Benefits One application One set of authorisations One set of documents to upload HRA accepts responsibility for their assessment NHS sites in England must have regard for HRA guidance Allows NHS sites to focus on set up and delivery

Should now be default option for new studies IRAS

Still have the function to create an SSI-but should not be used IRAS

HRA Review and Conclusion Initial Assessment An initial assessment is performed to confirm is the study eligible? If so an initial assessment letter is issued. Letter will clarify arrangements for different site types Flags issues to be resolved so sites don t replicate Review The HRA assessment will assess for compliance and other related matters and liaise with the sponsor of nominated individuals Conclusion Once assessment is completed, HRA conclusion- Approved or Not Approved -will be issued in the form of a letter HRA approval letter will state whether a model agreement is to be used for contracting MHRA approval is currently separate, but HRA approval is only issued when MHRA approval is in place

Statement of Activity & Schedule of Events NON COMMERCIAL TRIALS ONLY Download from HRA website Sponsor and study team should complete Attach to IRAS http://www.hra.nhs.uk/resources/hra-approvalapplicant-guidance/statement-activities-hraapproval/

Statement of Activities Acts as an agreement for simple studies A template per site type should be submitted to the HRA for review Sites will complete as part of the set up process

Schedule of Events Details activities and cost attribution at site A template per site type should be submitted to the HRA for review HRA approval will not be conditional on correct attribution of costs

Local submission NUH will be informed by the sponsor or HRA they have been selected as a site (NUH listed on IRAS). No need to submit to NUH via email If study is awaiting HRA approval, if appropriate Assess Arrange Confirm can begin If study is open already, AAC will begin immediately For studies where the HRA have said confirmation of capacity is not required, NUH will still look at the documents to ensure there is no risk of burden to staff or patients You should not start recruiting until NUH have confirmed you are OK to do so.

NUH review- Assess, Arrange, Confirm Study milestones- recruitment, start and end dates, follow up information, regulatory approvals Capacity- support departments, staffing resource Capability- do we see these patients, is the trial deliverable? Study action plan documentation to be completed by RPM/RM&G reviewer. Only when this has been completed is CAPACITY & CAPABILITY CONFIRMED

Local Information Pack In order to begin Assess, Arrange, Confirm we need the following from the sponsor:

Site set up stages

Studies involving Devolved English led Nations HRA will share the study-wide review SSIs submitted to Devolved Nations sites Led from Devolved Nations Ethics service shares their review with the HRA HRA will conduct their assessment and issue approval Have to accept SSI s at site, but still only confirming capacity and capability

Amendments Historic Studies When CSP is switched off amendments will go through the HRA Applies to ALL amendments for ALL studies (adopted and non adopted) Addition of new sites Will go through HRA via a light touch assessment Send e mail to hra.approval@nhs.net with study documentation For non commercial- schedule of events and statement of activities should also be completed

Amendments REC Approval Those requiring approval, continue to submit to REC that initially reviewed the study and info will be shared with HRA internally Non substantial amendments (not requiring REC) submit to hra.amendments@nhs.net Categorisation HRA assessment staff will categorise as A, B or C and inform the applicant of the categorisation. This will be completed within 5 working days A or B requires consideration by site- can be implemented 35 calendar days after sponsor provides information unless concerns/objections raised C does not require consideration by site so can be implemented immediately

Timelines Timelines are in calendar days with no clock stop

The future No SSI No governance review- NUH will confirm capacity and capability No CSP system Radiation and pharmacy technical assurance will be centralcurrently in final stages before roll out For further information please visit http://www.hra.nhs.uk/ Slides can be downloaded from http://nuhrise.org/training/ Contact R&I if you have further questions